In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative ( = 333) and Gram-positive ( = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL,...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 66; no. 2; p. e0216521
Main Authors Hackel, Meredith A, Karlowsky, James A, Canino, Michele A, Sahm, Daniel F, Scangarella-Oman, Nicole E
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 15.02.2022
Subjects
Acenaphthenes - pharmacology
Anti-Bacterial Agents - pharmacology
Bacteriology
Gram-Positive Bacteria
Heterocyclic Compounds, 3-Ring - pharmacology
Microbial Sensitivity Tests
Susceptibility
topoisomerase
inhibitor
anaerobes
gepotidacin
triazaacenaphthylene
Online AccessGet full text

Cover

More Information
Summary:Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative ( = 333) and Gram-positive ( = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. Given gepotidacin's activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the treatment of infections caused by clinically relevant anaerobic organisms.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare a conflict of interest. M.A.C. and N.E.S.-O. are employees and shareholders of GlaxoSmithKline. J.A.K. is a consultant to IHMA. M.A.H. and D.F.S. are employees of IHMA. The IHMA authors do not have personal financial interests in GlaxoSmithKline.
Present address: Michele A. Canino, Janssen Biotech, Inc., Malvern, PA.
ISSN:0066-4804
1098-6596
1098-6596
DOI:10.1128/aac.02165-21